《新股消息》先声药业(02096.HK)公开超购588倍及上限定价 一手中签率仅5%
内地生物化学制药集团先声药业(02096.HK)公布招股结果,计划发售2.61亿股新股,公开发售录超购588.47倍,经重新分配後,公开发售股数增至50%,国际发售项下初步提呈发售的发售股份获超额认购约23倍;一手1,000股中签率仅为5%。该股将於下周二(10月27日)上市。摩根士丹利及中金为联席保荐人。
每股发售价定於13.7元,为上限定价(招股价介乎12.1至13.7元),是次上市公司引入7名基石投资者,包括HillhouseCapital、红土及高新等,合共认购1.07亿股股份。
先声药业预计所得款项净额将约为33.92亿元,当中60%将用於持续研发在战略重点治疗领域中选定的在研产品;10%将用於加强集团销售及营销能力;10%将用於未来几年投资医药或生物技术领域的公司;10%将用於偿还若干未偿还银行贷款;余下10%为营运资金及其他一般企业用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.